Clinical and Applied Thrombosis/Hemostasis

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to start reading!

Click here to browse AJSM online!

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via ISI Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Michiels, J. J.
Right arrow Articles by van Vliet, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Michiels, J. J.
Right arrow Articles by van Vliet, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Clinical and Applied Thrombosis/Hemostasis, Vol. 12, No. 4, 397-420 (2006)
DOI: 10.1177/1076029606293422

Classification and Characterization of Hereditary Types 2A, 2B, 2C, 2D, 2E, 2M, 2N, and 2U (Unclassifiable) von Willebrand Disease

Jan Jacques Michiels, MD, PhD

Hemostasis and Thrombosis Research, Department of Hematology, University Hospital Antwerp, Belgium, Hemostasis and Thrombosis Research Science Center, Goodheart Institute, Rotterdam, The Netherlands, jan.michiels{at}uza.be

Zwi Berneman, MD, PhD

Hemostasis and Thrombosis Research, Department of Hematology, University Hospital Antwerp, Belgium

Alain Gadisseur, MD

Hemostasis and Thrombosis Research, Department of Hematology, University Hospital Antwerp, Belgium

Marc van der Planken, MD

Hemostasis and Thrombosis Research, Laboratory of Hematology and Hemostasis, Department of Clinical Pathology, University Hospital Antwerp, Belgium

Wilfried Schroyens, MD, PhD

Hemostasis and Thrombosis Research, Department of Hematology, University Hospital Antwerp, Belgium

Ann van de Velde, MD

Hemostasis and Thrombosis Research, Department of Hematology, University Hospital Antwerp, Belgium

Huub van Vliet, PhD

Hemostasis Thrombosis Research, Erasmus Medical Center, Academic Hospital Dijkzigt, Rotterdam, The Netherlands

All variants of type 2 von Willebrand disease (VWD) patients, except 2N, show a defective von Willebrand factor (VWF) protein (on cross immunoelectrophoresis or multimeric analysis), decreased ratios for VWF:RCo/Ag and VWF:CB/Ag and prolonged bleeding time. The bleeding time is normal and FVIII:C levels are clearly lower than VWF:Ag in type 2N VWD. High resolution multimeric analysis of VWF in plasma demonstrates that proteolysis of VWF is increased in type 2A and 2B VWD with increased triplet structure of each visuable band (not present in types 2M and 2U), and that proteolysis of VWF is minimal in type 2C, 2D, and 2E variants that show aberrant multimeric structure of individual oligomers. VWD 2B differs from 2A by normal VWF in platelets, and increased ristocetine-induced platelet aggregation (RIPA). RIPA, which very likely reflects the VWF content of platelets, is normal in mild, decreased in moderate, and absent in severe type 2A VWD. RIPA is decreased or absent in 2M, 2U, 2C, and 2D, variable in 2E, and normal in 2N. VWD 2M is usually mild and characterized by decreased VWF:RCo and RIPA, a normal or near normal VWF multimeric pattern in a low resolution agarose gel. VWD 2A-like or unclassifiable (2U) is distinct from 2A and 2B and typically featured by low VWF:RCo and RIPA with the relative lack of high large VWF multimers. VWD type 2C is recessive and shows a characteristic multimeric pattern with a lack of high molecular weight multimers, the presence of one single-banded multimers instead of triplets caused by homozygosity or double hereozygosity for a mutation in the multimerization part of VWF gene. Autosomal dominant type 2D is rare and characterized by the lack of high molecular weight multimers and the presence of a characteristic intervening subband between individual oligimers due to mutation in the dimerization part of the VWF gene. In VWD type 2E, the large VWF multimers are missing and the pattern of the individual multimers shows only one clearly identifiable band, and there is no intervening band and no marked increase in the smallest oligomer. 2E appears to be less well defined, is usually autosomal dominant, and accounts for about one third of patients with 2A in a large cohort of VWD patients.

Key Words: von Willebrand factor • von Willebrand disease • Ristocetin cofactor activity • von Willebrand collagen binding activity • Factor VIII:C • Bleeding time • DDAVP

References

  • Goodeve A, Peake I. A standard nomenclature for von Willebrand factor gene mutations and polymorphisms. Baillieres Clin Haematol 2001; 14: 235-235.
  • De Wit TR, Van Mourik JA. Biosynthesis, processing and secretion of von Willebrand factor: Biological implications. Baillieres Clin Haematol 2001; 14: 241-241.
  • Ruggeri ZM. Structure of von Willebrand factor and its function in platelet adhesion and thrombus formation. Baillieres Clin Haematol 2001; 14: 257-257.
  • Sadler JE. A revised classification of von Willebrand disease. Thromb Haemost 1994; 71: 520-520.[ISI][Medline] [Order article via Infotrieve]
  • Zimmerman ThS, Dent JA, Ruggeri ZM, Nannini LH. Subunit composition of plasma von Willebrand factor. J Clin Invest 1986; 77: 947-947.[ISI][Medline] [Order article via Infotrieve]
  • Schneppenheim R, Budde U, Ruggeri ZM. A molecular approach to the classification of von Willebrand disease. Baillieres Clin Haematol 2001; 14: 281-281.
  • Michiels JJ, Van De Velde A, Van Vliet HHDM, et al. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: Diagnostic and therapeutic implications. Semin Thromb Hemost 2002; 28: 111-111.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Zhang Z, Lindstedt M, Blombäck M, Anvret M. Effects of mutant von Willebrand factor gene in von Willebrand disease. Hum Genet 1995; 96: 388-388.[ISI][Medline] [Order article via Infotrieve]
  • Eikenboom JCJ, Reitsma PH, Peerlinck KJM, Briët E. Recessive inheritance of von Willebrand’s disease. Lancet 1993; 341: 982-982.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Ivy AC, Nelson D, Bucher G. The standardization of certain factors in the cutaneous "venostasis" bleeding time technique. J Lab Clin Med 1941; 26: 1812-1812.[ISI]
  • Sramek R, Sramek A, Koster T, et al. A randomized and blinded comparison of 3 bleeding time techniques—The Ivy, and the Simplate II in 2 directions. Thromb Haemost 1992; 67: 357-357.[ISI][Medline] [Order article via Infotrieve]
  • Cejka J. Enzyme immunoassay for factor VIII-related antigen. Clin Chem 1984; 28: 1356-1356.
  • Budde U, Drewke E, Mainusch K, Schneppenheim R. Laboratory diagnosis of congenital von Willebrand disease. Semin Thromb Hemost 2002; 28: 173-173.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Brown JE, Bosak JO. An ELISA test for the binding of von Willebrand factor antigen to collagen. Thromb Res 1986; 43: 303-303.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Favaloro EJ. Von Willebrand factor collagen-binding (activity) assay in the diagnosis of von Willebrand disease: A 15-year journey. Semin Thromb Hemost 2002; 28: 191-191.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Hubbard AR, Sands D, Chang AC, Mazurier C. Standardization of von Willebrand factor in therapeutic concentrates: Calibration of the 1st International Standard for von Willebrand factor concentrate (00/514). Thromb Haemost 2002; 88: 380-380.[ISI][Medline] [Order article via Infotrieve]
  • Favaloro EJ, Smith J, Petinos P, et al. Laboratory testing for von Willebrand’s disease: An assessment of current diagnostic practice and efficacy by means of a multi-laboratory survey. Thromb Haemost 1999; 82: 1276-1276.[ISI][Medline] [Order article via Infotrieve]
  • Favaloro EJ. Collagen binding assay for von Willebrand factor (VWF:CBA) detection of von Willebrand disease (VWD) and discrimination of VWD subtypes depends on collagen source. Thromb Haemost 2000; 83: 127-127.[ISI][Medline] [Order article via Infotrieve]
  • Favaloro EJ, Bukuya M, Martinelli T, et al. A comparative multi-laboratory assessment of three factor/von Willebrand factor concentrates. Thromb Haemost 2002; 87: 466-466.[ISI][Medline] [Order article via Infotrieve]
  • Neugebauer BM, Goy C, Budek I, Setitz R. Comparison of two von Willebrand factor collagen-binding assays with different binding affinities for low, medium and high multimers of von Willebrand factor. Semin Thromb Hemost 2002; 28: 139-139.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Mazurier C, Meyer D. Factor VIII binding of von Willebrand factor and the diagnosis of type 2N von Willebrand disease. Thromb Haemost 1996; 76: 270-270.[ISI][Medline] [Order article via Infotrieve]
  • Brosstad F, Kjonniksen I, Ronning B, Stromorken H. Visualization of von Willebrand factor multimers by enzyme-conjugated secondary antibodies. Thromb Haemost 1986; 55: 276-276.[ISI][Medline] [Order article via Infotrieve]
  • Eikenboom JCJ, Castaman G, Kamphuisen PW, et al. The factor VIII/von Willebrand factor ratio discriminates between reduced synthesis and increased clearance of von Willebrand factor. Thromb Haemost 2002; 87: 252-252.[ISI][Medline] [Order article via Infotrieve]
  • Peake IA, Bloom AL, Giddings JC. Inherited variants of FVIII-VIII-related protein in von Willebrand’s disease. N Engl J Med 1974; 291: 113-113.[ISI][Medline] [Order article via Infotrieve]
  • Green D, Philip KJ. Variant von Willebrand’s disease. Thromb Haemost 1980; 43: 2-2.[ISI][Medline] [Order article via Infotrieve]
  • Hill FGH, Enayat MS, George AJ. Investigation including VIIIR:AG multimeric analysis of a large kindred with type IIA von Willebrand’s disease showing a dominant inheritance and similar gene expression in four generations. Thromb Haemost 1983; 50: 735-735.[ISI][Medline] [Order article via Infotrieve]
  • Ruggeri ZM, Pareti FI, Mannucci PM, et al. Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand’s disease. N Engl J Med 1980; 302: 1047-1047.[Abstract]
  • Nichols W, Ginsburg D. Von Willebrand disease. Medicine 1997; 76: 1-1.[CrossRef][Medline] [Order article via Infotrieve]
  • Meyer D, Fressinaud E, Gaucher C, et al. Gene defects in 150 unrelated French cases with type 2 von Willebrand disease: From the patient to the gene. Thromb Haemost 1997; 78: 451-451.[ISI][Medline] [Order article via Infotrieve]
  • Meyer D, Fressinaud E, Hilbert L, et al. Type 2 von Willebrand disease causing defective von Willebrand factor-dependent platelet function. Baillieres Clin Haematol 2001; 14: 349-349.
  • Castaman G, Federici AB, Rodeghiero F, Mannucci PM. Von Willebrand’s disease in the year 2003: Towards the complete identification of gene defects for correct diagnosis and treatment. Haematologica 2003; 88: 94-94.[Abstract/Free Full Text]
  • Lyons SE, Bruck ME, Bowie EJW, Ginsburg D. Impaired intracellular transport by a subset of type IIA von Willebrand disease mutations. J Biol Chem 1992; 267: 4424-4424.[Abstract/Free Full Text]
  • Federici AB, Mazurier C, Berntorp E, et al. Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: Results of a multicenter European study. Blood 2004; 103: 2032-2032.[Abstract/Free Full Text]
  • Batlle J, Lopez-Fernandez MF, Campos M, et al. The heterogeneity of type IIA von Willebrand’s disease. Blood 1986; 68: 1207-1207.[Abstract/Free Full Text]
  • Batlle J, Lassieri J, Villamor AF, et al. Proteolytic rocessing of von Willebrand factor subunit: Heterogeneity in type IIA von Willebrand disease. Ann Hematol 1994; 68: 111-111.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Holmberg L, Berntopr E, Donner M, Noilsson IM. Von Willebrand’s disease characterized by increased ristocetin sensitivity and the presence of all von Willebrand factor multimers in plasma. Blood 1986; 68: 668-668.[Abstract/Free Full Text]
  • Weiss HJ, Sussman I. A new von Willebrand variant (type 1, New York): Increased ristocetin-induced platelet aggregation and plasma von Willebrand factor containing the full range of multimers. Blood 1986; 68: 149-149.[Abstract/Free Full Text]
  • Firkin B, Firkin F, Stott L. Von Willebrand’s disease type B: A newly defined bleeding diathesis. Aust N Z Med 1973; 3: 225-225.
  • Howard MA, Salem HH, Thomas KB, et al. Variant von Willebrand’s disease type B—Revisited. Blood 1982; 60: 1420-1420.[Abstract/Free Full Text]
  • Raboniwitz I, Tuley EA, Mancuso DJ, et al. Von Willebrand disease type B: A missence mutation selectively abolishes ristocetine-induced von Willebrand binding to platelet glycoprotein Ib. Proc Natl Acad Sci USA 1992; 89: 9846-9846.[Abstract/Free Full Text]
  • Sadler JE, Mannucci PM, Berntorp E, et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 2000; 84: 160-160.[ISI][Medline] [Order article via Infotrieve]
  • Mannucci PM, Lombardi R, Bader R, et al. Heterogeneity of type I von Willebrand disease: Evidence for a subgroup with abnormal von Willebrand factor. Blood 1985; 66: 796-796.[Abstract/Free Full Text]
  • Federici AB, Canciani MT, Forza I, et al. Ristocetin cofactor and collagen binding activities normalized to antigen levels for a rapid diagnosis of type 2 von Willebrand disease. Thromb Haemost 2000; 84: 1127-1127.[ISI][Medline] [Order article via Infotrieve]
  • Hoyer LW, Rizza CR, Tuddenham GD, et al. Von Willebrand factor multimer patterns in von Willebrand’s disease. Br J Haematol 1983; 55: 493-493.[ISI][Medline] [Order article via Infotrieve]
  • Mancusco DJ, Kroner PhA, Christopherson PM, et al. Type 2M:Milwaukee-1 von Willebrand disease with an in-frame deletion in the Cys509-Cys695 loop of the von Willebrand factor A1 domain causes deficient binding of von Willebrand to platelets. Blood 1996; 88: 2559-2559.[Abstract/Free Full Text]
  • Hillery CA, Mabcusco DJ, Sadler JE, et al. Type 2M von Willebrand disease: F606I and I662F mutations in the glycoprotein Ib binding domain selectively impair ristocetin—but not botrocetin-mediated binding of von Willebrand factor to platelets. Blood 1998; 91: 1572-1572.[Abstract/Free Full Text]
  • Hilbert L, Jenkins PV, Gaucher G, et al. Type 2M vWD resulting from a lysine deletion within a four lysine residue repeat in the A1 loop of von Willebrand factor. Thromb Haemost 2000; 84: 188-188.[ISI][Medline] [Order article via Infotrieve]
  • Nitu-Whalley IC, Ridell A, Lee C, et al. Identification of type 2 von Willebrand disease in previously diagnosed type 1 patients: A reappraisal using phenotypes, genotypes and molecular modelling. Thromb Haemost 2000; 84: 998-998.[ISI][Medline] [Order article via Infotrieve]
  • Lethagen S, Frick K, Isaksson C, et al. Revised classification and treatment of von Willebrand disease. Thromb Haemost 1998; 80: 199-199.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Castaman G, Eikenboom JCJ, Rodeghiero F, et al. A novel candidate mutation (Arg611 ØHis) in type I "platelet discordant" von Willebrand disease with desopressine-induced thrombocytopenia. Br J Haematol 1995; 89: 656-656.[ISI][Medline] [Order article via Infotrieve]
  • Hilbert L, Gaucher C, Mazurier C. Idenfication of two mutations (Arg611Cys and Arg611His) in the A1 loop of von Willebrand factor (VWF) responsible for type 2 von Willebrand disease with decreased platelet-dependent function of VWF. Blood 1995; 86: 1010-1010.[Abstract/Free Full Text]
  • Nishikubo T, Christophe O, Lavergne J-M, et al. Abnormal proteolytic processing of von Willebrand factor Arg611Cys and Arg611His. Thromb Haemost 1997; 77: 174-174.[ISI][Medline] [Order article via Infotrieve]
  • Ribba AS, Hilbert L, Lavergne JM, et al. The Arg552Cys (R552C) mutation within the A1 loop of von Willebrand factor (VWF) induces abnormal folding with loss-of-function resulting in 2A-like phenotype of von Willebrand disease. Study of ten patients and of mutated recombinant VWF. Blood 2001; 97: 952-952.[Abstract/Free Full Text]
  • Ruggeri ZA, Nilsson IM, Lombardi R, et al. Aberrant multimeric structure of von Willebrand factor in a new variant of von Willebrand’s disease (type IIC). J Clin Invest 1982; 70: 1124-1124.[ISI][Medline] [Order article via Infotrieve]
  • Holmberg L, Karpman D, Isakson C, et al. Ins405AsnPro mutation in the von Willebrand factor propeptide in recessive type 2A (IIC) von Willebrand’s disease. Thromb Haemost 1998; 79: 718-718.[ISI][Medline] [Order article via Infotrieve]
  • Mazurier C, Manucci PM, Parquet-Gernez A, et al. Investigation of a case of subtype IIC von Willebrand disease: Characterization of the variability of this subtype. Am J Hematol 1986; 22: 301-301.[ISI][Medline] [Order article via Infotrieve]
  • Gaucher C, Diéval J, Mazurier C. Characterization of von Willebrand factor gene defects in two unrelated patients with type IIC von Willebrand disease. Blood 1994; 84: 1024-1024.[Abstract/Free Full Text]
  • Battle J, Lopez-Fernandez MF, Lasiera J, et al. Von Willebrand disease type IIC with different abnormalities of von Willebrand factor in the same sibship. Am J Hematol 1986; 21: 177-177.[ISI][Medline] [Order article via Infotrieve]
  • Battle J, Lopez Gernandez MF, FernandezVillamor A, et al. Multimeric pattern discrepancy between platelet and plasma von Willebrand factor in type IIC von Willebrand disease. Am J Hematol 1986; 22: 87-87.[ISI][Medline] [Order article via Infotrieve]
  • Schneppenheim R, Thomas KB, Krey S, et al. Identification of a candidate missense mutation in a family with von Willebrand disease type IIC. Hum Genet 1995; 95: 681-681.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Mannucci PM, Lombardi R, Pareti FI, et al. A variant of von Willebrand’s disease characterized by recessive inheritance and missing triplet structure of von Willebrand factor multimers. Blood 1983; 62: 1000-1000.[Abstract/Free Full Text]
  • Kinoshita S, Harrison J, Lazerson J, Abildgaard CF. A new variant of dominant type II von Willebrand’s disease with aberrant multimeric pattern of factor VIII-related antigen (type IID). Blood 1984; 63: 1369-1369.[Abstract/Free Full Text]
  • Schneppenheim R, Brassard J, Krey S, et al. Defective dimerization of von Willebrand factor subunits due to a Cys ØArg mutation in type IID von Willebrand disease. Proc Natl Acad Sci USA 1996; 93: 3581-3581.[Abstract/Free Full Text]
  • Schneppenheim R, Budde U, Obser T, et al. Expression and characterization of von Willebrand factor dimerization defects in different types of von Willebrand disease. Blood 2001; 97: 2059-2059.[Abstract/Free Full Text]
  • Balloid P, Gaucher C, Affolter B, et al. New variant of type II von Willebrand’s disease with structural abnormality of plasma von Willebrand factor in a patient with very mild bleeding history. Am J Hematol 1995; 49: 21-21.[ISI][Medline] [Order article via Infotrieve]
  • Gaucher C, Parquet A, Baillod P, et al. Mutations in the D3 domain of von Willebrand factor are identified in patients classified as 1 or 2A von Willebrand disease. Thromb Haemost 1997 (suppl): 388-388 (abstract OC-1583).
  • Castaman G, Rodeghiero F, Lattuada A, Mannucci PM. A new variant of von Willebrand disease (type II I) with a normal degree of proteolytic cleavage of von Willebrand factor. Thromb Res 1992; 65: 343-343.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Ledford M, Rabinowitz I, Sadler JE, et al. Newriant of von Willebrand disease type II with markedly increased levels of von Willebrand antigen and dominant mode of inheritance: von Willebrand disease type IIC Miami. Blood 1993; 82: 169-169.[Abstract/Free Full Text]
  • Mannucci PM, Lombardi R, Federici AB, et al. A new variant of type II von Willebrand disease with aberrant multimeric structure of plasma but not platelet von Willebrand factor (type IIF). Blood 1986; 68: 269-269.[Abstract/Free Full Text]
  • Gralnick HR, Williams SB, McKeown LP, et al. A variant of type II von Willebrand disease with an abnormal triplet structure and discordant effects of protease inhibitors on plasma and platelet von Willebrand factor structure. Am J Hematol 1987; 24: 259-259.[ISI][Medline] [Order article via Infotrieve]
  • Federici AB, Manuccio PM, Lombardi R, et al. Type II H von Willebrand disease: New structural abnormality of plasma and platelet von Wilebrand factor in a patients with prolonged bleeding time and borderline levels of ristocetin cofactor activity. Am J Hematol 1989; 32: 287-287.[ISI][Medline] [Order article via Infotrieve]
  • Lopez-Fernandez MF, Gonzalez-Boullousa R, Blanco-Lopez MJ, et al. Abnormal proteolytic degradation of von Willebrand factor after desmopressin infusion in a new subtype of von Willebrand disease (1D). Am J Hematol 1991; 36: 163-163.[ISI][Medline] [Order article via Infotrieve]
  • Ciavarelli G, Ciavarelli N, Antoncecchi S, et al. High-resolution analysis of von Willebrand factor multimeric composition defines a new variant of type I von Willebrand disease with aberrant structure but presence of all size multimers (type IC). Blood 1985; 66: 1423-1423.[Abstract/Free Full Text]
  • Mazurier C. Von Willebrand disease masquerading as haemophilia A. Thromb Haemost 1992; 67: 391-391.[ISI][Medline] [Order article via Infotrieve]
  • Mazurier C, Goudemand J, Hilbert L, et al. Type 2N von Willebrand disease: Clinical manifestations, pathophysiology. Laboratory diagnosis and molecular biology. Baillieres Clin Haematol 2001; 14: 337-337.
  • Schneppenheim R, Budde U, Krey S, et al. Results of a screening for von Willebrand disease type 2N in patients with suspected haemophilia A or von Willebrand disease type 1. Thromb Haemost 1996; 76: 598-598.[ISI][Medline] [Order article via Infotrieve]
  • Mazurier C, Gaucher C, Joriuex S, Goudemand M. Biological effect of desmopressin in eight patients with type 2N ("Normandy") von Willebrand disease. Br J Haematol 1994; 88: 849-849.[ISI][Medline] [Order article via Infotrieve]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via ISI Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Michiels, J. J.
Right arrow Articles by van Vliet, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Michiels, J. J.
Right arrow Articles by van Vliet, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?